Most Popular
-
1
1 in 3 Koreans live alone, family types becoming diverse
-
2
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
3
K-pop group's manager dismissed for setting up spycam in theater dressing room
-
4
Contentious grain bill put directly to plenary meeting for vote
-
5
Why is Apple Pay struggling to get purchase in Korea?
![[Today’s K-pop] BTS pop-up event to come to Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/17/20240417050734_0.jpg&u=)
South Korean pharmaceutical giant Yuhan has established a subsidiary in Australia to expand its global clinical network and drug development pipelines.
The subsidiary, Yuhan ANZ, was launched in June. Some 2 billion won ($1.6 million) was reportedly invested for the project.
The company said Australia is one of the countries with bright prospects for the pharmaceutical market, given its increasing demand for medical products.
“Launching a subsidiary in Australia is a part of our efforts to expand (drug development) pipelines,” said an official from Yuhan. “Specific business plans have yet to be determined.”
According to the Korea Trade-Investment Promotion Agency, the country’s market volume is expected to reach $14.8 billion by 2022, compared to $11.8 billion in 2017.
Under the company’s Open Innovation Initiative, Yuhan has been making a foray into the global market to develop new drugs and medical technology.
Last year, the company established subsidiaries in San Francisco and Boston to boost its presence in the world’s biggest pharmaceutical market.
Yuhan’s subsidiary in Australia is also aimed at supporting efforts related to market expansion and product diversification, the company said.
(jasonyeo@heraldcorp.com)
![[KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/18/20240418050645_0.jpg&u=20240419100350)
